Pablo Marco-Moreno

Pablo Marco-Moreno

Auto-generated profile, based on publicly available information

Pablo Marco-Moreno

Group of Neuromuscular Diseases, Donostia University Hospital Biodonostia‐Biogipuzkoa Health Research Institute Donostia‐San Sebastián Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
CVCamila Vesga-Castro
Camila Vesga-Castro
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
PUPaul Ubiria-Urkola
Paul Ubiria-Urkola
PMPablo Marco-Moreno
Pablo Marco-Moreno
KGKlaudia González-Imaz
Klaudia González-Imaz
JPJacobo Paredes
Jacobo Paredes
This 2D human muscle system, μGrooves, promote myoblast alignment and fusion and enhance myotubes differentiation. Robust high-content assays of functional outcomes, contractility and calcium, are made with increased sensitivity and reproducibility.

1 January 2025 in European Journal of Neurology
Verified
Journal Article
Open access
ASAlba Segarra‐Casas
Alba Segarra‐Casas
PIPablo Iruzubieta
Pablo Iruzubieta
SKSolange Kapetanovic
Solange Kapetanovic
AHAurelio Hernández‐Laín
Aurelio Hernández‐Laín
IJIvonne Jericó
Ivonne Jericó
Lidia Gonzalez-QueredaLidia Gonzalez-Quereda
Lidia Gonzalez-Quereda
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant.Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives.Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non‐specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype.Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.

1 July 2026 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
LFLourdes C. Figueroa
Lourdes C. Figueroa
ETEshwar Reddy Tammineni
Eshwar Reddy Tammineni
PMPablo Marco-Moreno
Pablo Marco-Moreno
AVAinara Vallejo-Illarramendi
Ainara Vallejo-Illarramendi
AMAdolfo López de Munain
Adolfo López de Munain
CMCarlo Manno
Carlo Manno
Doxorubicin (DOX), a widely used chemotherapy agent, causes off-target cytotoxicity in healthy cells and often leads to debilitating skeletal muscle fatigue and weakness. In this study, we examined the effects of DOX on excitation-contraction coupling. From single RyR1 channel properties to muscle force production, we identified the underlying mechanisms of muscle dysfunction. We also evaluated novel small molecules that normalize calcium release, highlighting potential therapeutic strategies to prevent DOX-induced skeletal myopathy (DISM).

13 November 2025 in bioRxiv
Verified
Preprint
Open access
LFLourdes C. Figueroa
Lourdes C. Figueroa
ETEshwar Reddy Tammineni
Eshwar Reddy Tammineni
PMPablo Marco-Moreno
Pablo Marco-Moreno
AVAinara Vallejo-Illarramendi
Ainara Vallejo-Illarramendi
AMAdolfo López de Munain
Adolfo López de Munain
CMCarlo Manno
Carlo Manno
Doxorubicin (DOX), a highly effective and widely used chemotherapeutic agent used to treat various types of cancer. Unfortunately, DOX also has some undesirable and off-target effects, particularly debilitating muscle weakness and fatigue. The mechanism behind this DOX-induced skeletal myotoxicity (DISM) remains unclear. Here, we show that acute DOX exposure, at clinically relevant concentrations, impairs isometric force production and accelerates fatigue in ex vivo murine flexor digitorum brevis (FDB) muscles. Mechanistically, we found that DOX increases the open probability of single RyR1 and disrupts calcium (Ca 2+ )-dependent inactivation (CDI). This results in a persistent sarcoplasmic reticulum (SR) Ca 2+ leak, elevated basal cytosolic Ca 2+ , and abnormal Ca 2+ release during action potentials. This abnormal intracellular Ca 2+ handling ultimately leads to increased mitochondrial reactive oxygen species (ROS) production, which, in turn, exacerbates the functional instability of RyR1. Interestingly, the cytosolic basal Ca 2+ elevation precedes ROS generation, suggesting that it initiates a destructive cross-talk between Ca 2+ dysregulation and oxidative stress. Notably, pharmacological stabilization of the RyR1-FKBP12 complex with novel triazole compounds, MP-001 and MP-034, normalizes RyR1 function, Ca 2+ and ROS homeostasis, as well as muscle force and fatigue resistance. Our findings indicate that DISM is initiated by DOX destabilization of the RyR1-FKBP12 complex (abnormal SR Ca 2+ leak) and then exacerbated by the Ca-ROS vicious cycle. Limiting RyR1-mediated Ca 2+ leak with MP-001 represents a promising therapeutic strategy for anti-DISM, aiming to normalize muscle function in patients undergoing DOX chemotherapy.